TrialThoracic cancer2023

Phase II trial of daily S-1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan lung cancer group 1101.

Yosuke Kawashima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.